Developer docs
API playgroundTry for free, no card

Search company profiles

Acrivon Therapeutics

Full company profile

uuid000082s

Namestring
Acrivon Therapeutics
Legal namestring
Acrivon Therapeutics, Inc.
Websiteurl
acrivon.com
Company typeenum
Public
Founded yearint
2018
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision oncology therapeutics, targeted cancer therapies, companion diagnostic tests, phosphoproteomics drug discovery, DNA damage response inhibitors
Industry3 codes
PRIMARYHLAAANAC
Companion Diagnostics (CDx) Development & Commercialization
SECONDARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Precision Oncology Therapeutics
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Commercialization
TypeLicensing Royalties
Description

Acrivon is a clinical-stage precision oncology company focused on developing targeted cancer therapies. As an unprofitable biotech, it has no current revenue. Future revenue will come from commercialization of drug candidates upon regulatory approval, with potential for co-development partnerships and licensing arrangements.

acrivon.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Acrivon Therapeutics is a clinical-stage precision oncology company developing targeted cancer therapies paired with proprietary OncoSignature companion diagnostics. Its lead program ACR-368 (a CHK1/2 inhibitor in-licensed from Eli Lilly) is in registrational-intent Phase 2b for endometrial cancer and platinum-resistant ovarian cancer, supported by the AP3 platform that uses mass spectrometry-based phosphoproteomics with automated tumor biopsy imaging to match drug mechanisms to protein-activity-driven tumor biology rather than genomic alterations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 52% confirmed overall response rate in serous endometrial cancer patients (ACR-368 Phase 2b)
+3 more records
Product overview1 text field

Acrivon Therapeutics is a clinical-stage precision oncology company developing a pipeline of targeted cancer therapies powered by its proprietary AP3 (Acrivon Predictive Precision Proteomics) platform. The company's portfolio includes three drug candidates: ACR-368 (lead program, CHK1/2 inhibitor in Phase 2 for endometrial cancer with FDA Fast Track designation), ACR-2316 (WEE1/PKMYT1 inhibitor in Phase 1/2), and ACR-6840 (CDK11 inhibitor in IND-enabling studies). These drug candidates are paired with the company's OncoSignature companion diagnostic tests, which use automated quantitative proteomic tissue imaging to identify patients whose tumors are predicted to be sensitive based on protein activity measurement rather than genomic alterations.

Product and service4 records
1ACR-368 (Prexasertib)
CategoryPrecision Oncology Drug Candidate (CHK1/2 Inhibitor)
Description

ACR-368 (prexasertib) is a clinically-advanced, potent selective kinase inhibitor of DNA Damage Response checkpoint kinases CHK1 and CHK2, demonstrating deep durable single-agent anti-tumor clinical activity including complete responses in platinum-resistant ovarian cancer and other high unmet need solid tumor types. It is paired with the OncoSignature companion diagnostic for patient selection and has shown a 52% confirmed overall response rate in serous endometrial cancer and a 67% overall response rate in OncoSignature-positive serous endometrial cancer patients in Phase 2b studies.

2ACR-2316
CategoryPrecision Oncology Drug Candidate (WEE1/PKMYT1 Inhibitor)
Description

ACR-2316 is a selective, dual WEE1/PKMYT1 inhibitor developed using Acrivon's AP3 platform and co-crystallography-driven design, currently in Phase 1/2 clinical trials for advanced solid tumors including lung cancer, demonstrating favorable tolerability with clinical activity including partial responses.

3ACR-6840
CategoryPrecision Oncology Drug Candidate (CDK11 Inhibitor)
Description

ACR-6840 is a development candidate targeting CDK11, being developed using the AP3 platform, with plans for Investigational New Drug (IND) application submission in Q4 2026.

4OncoSignature Companion Diagnostic
CategoryCompanion Diagnostic Test
Description

OncoSignature is a drug-tailored, automated, quantitative proteomic tissue imaging assay designed to identify patients most likely to benefit from Acrivon's drug candidates by measuring disease-driving protein activity from pretreatment tumor biopsies. It has received FDA Breakthrough Device Designation for endometrial and ovarian cancer patient selection.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

ACR-368 (also known as Prexasertib, LY2606368) was in-licensed from Lilly. Acrivon acquired rights to develop and commercialize this clinically-advanced CHK1/2 inhibitor for oncology indications using its proprietary AP3 platform and OncoSignature companion diagnostic for patient selection.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage precision oncology company using a proprietary genomics- and CRISPR-based SNIPRx platform to develop synthetic-lethal targeted therapies with patient-selection biomarkers, comparable to Acrivon's AP3 platform-driven, biomarker-stratified approach.

TypeDirect peer
Description

Precision oncology company leveraging functional genomics and synthetic lethality to develop targeted cancer therapies with biomarker-driven patient selection, overlapping directly with Acrivon's proteomics-driven precision oncology strategy.

TypeDirect peer
Description

Clinical-stage precision oncology company developing allosteric kinase inhibitors against oncogenic mutations, using its proprietary Mutation-Allostery-Pharmacology platform, comparable to Acrivon's platform-based, biomarker-driven targeted oncology approach.

TypeDirect peer
Description

Precision oncology company combining computational methods with structural biology and biochemistry to develop targeted therapies such as PI3Kα inhibitors, with a similar platform-driven approach to Acrivon's AP3.

TypeDirect peer
Description

Clinical-stage oncology company targeting chromatin regulatory systems through its proprietary Gene Traffic Control platform, comparable to Acrivon as a platform-based precision oncology company developing multiple targeted candidates.

TypeDirect peer
Description

Computational drug discovery platform company applying physics-based modeling and predictive analytics to design precision oncology therapeutics, comparable to Acrivon's AI/ML-enabled KaiSR and AP3 platform approach.

TypeEmerging player
Description

Tech-enabled drug discovery company combining high-throughput biology with AI/ML to identify precision oncology candidates, comparable as an AI-driven precision oncology platform competitor to AP3.

TypeEmerging player
Description

AI-driven precision medicine company combining generative AI with patient-derived data to design targeted oncology drugs, comparable to Acrivon's computational platform and biomarker-driven strategy.

TypeEmerging player
Description

Clinical-stage precision oncology company using AI and genomic biomarker platforms (RADR) to develop and repurpose oncology drugs, comparable in its AI-platform plus companion-diagnostic model to Acrivon.

TypeDirect peer
Description

Clinical-stage precision oncology company developing small molecules targeting fundamental cancer pathways, with a pipeline that overlaps Acrivon's focus on gynecologic and other solid tumor indications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Acrivon Therapeutics

Precision Oncology Therapeuticsacrivon.com

Acrivon Therapeutics firmographics

Firmographics
Name
Acrivon Therapeutics
Legal name
Acrivon Therapeutics, Inc.
Website
https://acrivon.com
Company type
Public
Founded year
2018
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

Acrivon Therapeutics industry classification

Industry
Product category
Precision Oncology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAANAC
Companion Diagnostics (CDx) Development & Commercialization
SECONDARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)

Keywords

  • Precision oncology therapeutics
  • Targeted cancer therapies
  • Companion diagnostic tests
  • Phosphoproteomics drug discovery
  • DNA damage response inhibitors

Where Acrivon Therapeutics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Acrivon Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Drug Development and Commercialization: Acrivon is a clinical-stage precision oncology company focused on developing targeted cancer therapies. As an unprofitable biotech, it has no current revenue. Future revenue will come from commercialization of drug candidates upon regulatory approval, with potential for co-development partnerships and licensing arrangements.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Acrivon Therapeutics product offering

Product offering

Core offering

Acrivon Therapeutics is a clinical-stage precision oncology company developing targeted cancer therapies paired with proprietary OncoSignature companion diagnostics. Its lead program ACR-368 (a CHK1/2 inhibitor in-licensed from Eli Lilly) is in registrational-intent Phase 2b for endometrial cancer and platinum-resistant ovarian cancer, supported by the AP3 platform that uses mass spectrometry-based phosphoproteomics with automated tumor biopsy imaging to match drug mechanisms to protein-activity-driven tumor biology rather than genomic alterations.

Product overview

Acrivon Therapeutics is a clinical-stage precision oncology company developing a pipeline of targeted cancer therapies powered by its proprietary AP3 (Acrivon Predictive Precision Proteomics) platform. The company's portfolio includes three drug candidates: ACR-368 (lead program, CHK1/2 inhibitor in Phase 2 for endometrial cancer with FDA Fast Track designation), ACR-2316 (WEE1/PKMYT1 inhibitor in Phase 1/2), and ACR-6840 (CDK11 inhibitor in IND-enabling studies). These drug candidates are paired with the company's OncoSignature companion diagnostic tests, which use automated quantitative proteomic tissue imaging to identify patients whose tumors are predicted to be sensitive based on protein activity measurement rather than genomic alterations.

Differentiator

Problem solved

Functional benefit

Products and services

  • ACR-368 (Prexasertib) ACR-368 (prexasertib) is a clinically-advanced, potent selective kinase inhibitor of DNA Damage Response checkpoint kinases CHK1 and CHK2, demonstrating deep durable single-agent anti-tumor clinical activity including complete responses in platinum-resistant ovarian cancer and other high unmet need solid tumor types. It is paired with the OncoSignature companion diagnostic for patient selection and has shown a 52% confirmed overall response rate in serous endometrial cancer and a 67% overall response rate in OncoSignature-positive serous endometrial cancer patients in Phase 2b studies.
  • ACR-2316 ACR-2316 is a selective, dual WEE1/PKMYT1 inhibitor developed using Acrivon's AP3 platform and co-crystallography-driven design, currently in Phase 1/2 clinical trials for advanced solid tumors including lung cancer, demonstrating favorable tolerability with clinical activity including partial responses.
  • ACR-6840 ACR-6840 is a development candidate targeting CDK11, being developed using the AP3 platform, with plans for Investigational New Drug (IND) application submission in Q4 2026.
  • OncoSignature Companion Diagnostic OncoSignature is a drug-tailored, automated, quantitative proteomic tissue imaging assay designed to identify patients most likely to benefit from Acrivon's drug candidates by measuring disease-driving protein activity from pretreatment tumor biopsies. It has received FDA Breakthrough Device Designation for endometrial and ovarian cancer patient selection.

Quantifiable outcome

  • 52% confirmed overall response rate in serous endometrial cancer patients (ACR-368 Phase 2b)
  • +3 more outcomes

Companies that use Acrivon Therapeutics

Customer profile

Segments3 records

Ideal customer profiles2 records

Acrivon Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Acrivon Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Eli Lilly and CompanycoreOEM/ Whitelabel/ Licensing PartnerACR-368 (also known as Prexasertib, LY2606368) was in-licensed from Lilly. Acrivon acquired rights to develop and commercialize this clinically-advanced CHK1/2 inhibitor for oncology indications using its proprietary AP3 platform and OncoSignature companion diagnostic for patient selection.

Scale indicators11 records

Recent moves6 records

Expansion highlights5 records

Acrivon Therapeutics competitors and assessment

Company assessment

Direct peers

  • Repare Therapeutics: Clinical-stage precision oncology company using a proprietary genomics- and CRISPR-based SNIPRx platform to develop synthetic-lethal targeted therapies with patient-selection biomarkers, comparable to Acrivon's AP3 platform-driven, biomarker-stratified approach.
  • Tango Therapeutics: Precision oncology company leveraging functional genomics and synthetic lethality to develop targeted cancer therapies with biomarker-driven patient selection, overlapping directly with Acrivon's proteomics-driven precision oncology strategy.
  • Black Diamond Therapeutics: Clinical-stage precision oncology company developing allosteric kinase inhibitors against oncogenic mutations, using its proprietary Mutation-Allostery-Pharmacology platform, comparable to Acrivon's platform-based, biomarker-driven targeted oncology approach.
  • Relay Therapeutics: Precision oncology company combining computational methods with structural biology and biochemistry to develop targeted therapies such as PI3Kα inhibitors, with a similar platform-driven approach to Acrivon's AP3.
  • Foghorn Therapeutics: Clinical-stage oncology company targeting chromatin regulatory systems through its proprietary Gene Traffic Control platform, comparable to Acrivon as a platform-based precision oncology company developing multiple targeted candidates.
  • Schrödinger: Computational drug discovery platform company applying physics-based modeling and predictive analytics to design precision oncology therapeutics, comparable to Acrivon's AI/ML-enabled KaiSR and AP3 platform approach.
  • Zentalis Pharmaceuticals: Clinical-stage precision oncology company developing small molecules targeting fundamental cancer pathways, with a pipeline that overlaps Acrivon's focus on gynecologic and other solid tumor indications.

Emerging players

  • Recursion Pharmaceuticals: Tech-enabled drug discovery company combining high-throughput biology with AI/ML to identify precision oncology candidates, comparable as an AI-driven precision oncology platform competitor to AP3.
  • Exscientia: AI-driven precision medicine company combining generative AI with patient-derived data to design targeted oncology drugs, comparable to Acrivon's computational platform and biomarker-driven strategy.
  • Lantern Pharma: Clinical-stage precision oncology company using AI and genomic biomarker platforms (RADR) to develop and repurpose oncology drugs, comparable in its AI-platform plus companion-diagnostic model to Acrivon.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Acrivon Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Acrivon Therapeutics leadership team

Management profile

Number of profiles

Profiles8 records

Acrivon Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Acrivon Therapeutics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Acrivon Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Acrivon Therapeutics

What does Acrivon Therapeutics do?

Acrivon Therapeutics is a clinical-stage precision oncology company developing targeted cancer therapies paired with proprietary OncoSignature companion diagnostics. Its lead program ACR-368 (a CHK1/2 inhibitor in-licensed from Eli Lilly) is in registrational-intent Phase 2b for endometrial cancer and platinum-resistant ovarian cancer, supported by the AP3 platform that uses mass spectrometry-based phosphoproteomics with automated tumor biopsy imaging to match drug mechanisms to protein-activity-driven tumor biology rather than genomic alterations.

Is Acrivon Therapeutics a public or private company?

Acrivon Therapeutics is a public company. It is classified as public and is currently operating.

When was Acrivon Therapeutics founded?

Acrivon Therapeutics was founded in 2018. It employs 51 to 100 people.

Where is Acrivon Therapeutics based?

Acrivon Therapeutics is headquartered in Cambridge, United States, in the North America region.

How does Acrivon Therapeutics make money?

One revenue line is on record: drug Development and Commercialization.

Who are Acrivon Therapeutics's main competitors?

Direct peers on record are Repare Therapeutics, Tango Therapeutics, Black Diamond Therapeutics, Relay Therapeutics, Foghorn Therapeutics, Schrödinger and Zentalis Pharmaceuticals. Emerging players are Recursion Pharmaceuticals, Exscientia and Lantern Pharma.

Does Acrivon Therapeutics have an API?

No public API is recorded for Acrivon Therapeutics.

What industry is Acrivon Therapeutics in?

Acrivon Therapeutics's product category is Precision Oncology Therapeutics. Its primary akta.pro industry code is HLAAANAC, Companion Diagnostics (CDx) Development & Commercialization, with a secondary code of HLAAANAF, Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comAcrivon Therapeutics CEO Peter Blume-Jensen sells $2,581 in stockAcrivon Therapeutics CEO Peter Blume-Jensen sold 1,780 shares at $1.45 on November 17, 2026, to satisfy tax withholding. The stock trades at $1.40, down 42% year-to-date, while Jefferies reiterated a Buy rating with a $14 price target.TradingViewCitizens maintains Acrivon Therapeutics at Market Outperform, keeps price target at $13Citizens maintained Acrivon Therapeutics at Market Outperform and kept its price target at $13. The target implies an upside of 790.4% from the Nov 16 close of $1.46.Defense WorldAcrivon Therapeutics (ACRV) Projected to Post Earnings on ThursdayAcrivon Therapeutics is expected to report Q3 2026 earnings on November 12th, with analysts projecting a loss of $0.45 per share and revenue of $0.50 million. The company's stock opened at $1.57, and analysts have a consensus rating of Moderate Buy with a target price of $13.50.Seeking AlphaAcrivon Therapeutics, Inc. (ACRV) Discusses ACR-525 Acquisition and PKC Inhibitor Preclinical Program TranscriptAcrivon Therapeutics announced the acquisition of two I&I assets, including ACR-525, an oral JAK1 inhibitor, and a PKC theta inhibitor preclinical program. The deal reflects the company's AI-driven AP3 platform strategy. The company will host a KOL panel to discuss the assets.American Banking and Market NewsAcrivon Therapeutics (NASDAQ:ACRV) Downgraded by Wall Street Zen to SellWall Street Zen downgraded Acrivon Therapeutics from hold to sell, while Weiss Ratings raised it from sell (e+) to sell (d-). The stock opened at $1.61 with a market cap of $68.99 million, and analysts predict a -1.76 EPS for the current year.TradingViewAcrivon Therapeutics Acquires Phase 2-Ready JAK1 and Preclinical PKCθ ProgramsAcrivon Therapeutics acquired an oral JAK1 inhibitor (ACR-525) and a preclinical PKCθ program, paying cash with no future milestone or royalty obligations. ACR-525 is Phase 2-ready for eosinophilic esophagitis, with potential in inflammatory bowel disease and other immune disorders.TradingViewAcrivon Therapeutics, Inc. (ACRV) Acquires Two Immunology ProgramsAcrivon Therapeutics acquired ACR-525, a Phase 2-ready oral JAK1 inhibitor, and a preclinical PKCθ inhibitor program from Aqilion AB for undisclosed cash consideration, with no future royalties or milestones. The acquisition adds immunology and inflammation assets, positioning ACR-525 for potential clinical advancement, though no trial start date or results were disclosed.Stock TitanAcrivon to present ACR-2316 data at EORTC-NCI-AACRAcrivon Therapeutics will present late-breaking oral plenary and poster presentations on ACR-2316 data at the EORTC-NCI-AACR Symposium in Barcelona, November 18-20, 2026. The presentations cover safety, dose optimization, and preliminary antitumor activity from a Phase 1 dose escalation study, as well as AP3-phosphoproteomics findings on ACR-2316's superior activity over WRN helicase inhibitors.Investing.comAcrivon to present cancer drug trial data at November symposiumAcrivon Therapeutics will present dose escalation data from its Phase 1/2 study of ACR-2316 at the 38th EORTC-NCI-AACR Symposium on November 20, 2026 in Barcelona. The trial showed clinical activity in endometrial and lung cancers, including a complete response in a lung cancer patient. The study is now in dose expansion, adding pancreatic cancer patients.TradingViewAcrivon Therapeutics, Inc. (ACRV) Reports Early ACR-2316 Responses; Expands StudyAcrivon Therapeutics reported early Phase 1/2 data for ACR-2316, showing confirmed complete and partial responses in lung and endometrial cancers. The company advanced to dose expansion, adding pancreatic ductal adenocarcinoma, with safety mainly transient neutropenia. The study may expand to include ICI and TOPO1 combinations.